First Axl inhibitor enters clinical trials - PubMed (original) (raw)
First Axl inhibitor enters clinical trials
Cormac Sheridan. Nat Biotechnol. 2013 Sep.
No abstract available
Similar articles
- Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer?
Dransfield I, Farnworth S. Dransfield I, et al. Adv Exp Med Biol. 2016;930:113-32. doi: 10.1007/978-3-319-39406-0_5. Adv Exp Med Biol. 2016. PMID: 27558819 Review. - Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S, Yamane Y, Tsukamoto S, Murai N, Azuma H, Nagao S, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13. Bioorg Med Chem Lett. 2021. PMID: 34271070 - Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Corno C, et al. Curr Med Chem. 2016;23(15):1496-512. doi: 10.2174/0929867323666160405112954. Curr Med Chem. 2016. PMID: 27048336 Review. - Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.
Keung W, Boloor A, Brown J, Kiryanov A, Gangloff A, Lawson JD, Skene R, Hoffman I, Atienza J, Kahana J, De Jong R, Farrell P, Balakrishna D, Halkowycz P. Keung W, et al. Bioorg Med Chem Lett. 2017 Feb 15;27(4):1099-1104. doi: 10.1016/j.bmcl.2016.12.024. Epub 2016 Dec 20. Bioorg Med Chem Lett. 2017. PMID: 28082036 - Axl inhibitors as novel cancer therapeutic agents.
Shen Y, Chen X, He J, Liao D, Zu X. Shen Y, et al. Life Sci. 2018 Apr 1;198:99-111. doi: 10.1016/j.lfs.2018.02.033. Epub 2018 Feb 27. Life Sci. 2018. PMID: 29496493 Review.
Cited by
- Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.
Duan Y, Hu B, Qiao C, Luo L, Li X, Wang J, Liu H, Zhou T, Shen B, Lv M, Feng J. Duan Y, et al. Oncol Lett. 2019 Jun;17(6):5784-5792. doi: 10.3892/ol.2019.10255. Epub 2019 Apr 15. Oncol Lett. 2019. PMID: 31186805 Free PMC article. - Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.
Poświata A, Kozik K, Miączyńska M, Zdżalik-Bielecka D. Poświata A, et al. Cell Mol Life Sci. 2022 May 27;79(6):316. doi: 10.1007/s00018-022-04312-3. Cell Mol Life Sci. 2022. PMID: 35622156 Free PMC article. - AXL kinase as a novel target for cancer therapy.
Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. Wu X, et al. Oncotarget. 2014 Oct 30;5(20):9546-63. doi: 10.18632/oncotarget.2542. Oncotarget. 2014. PMID: 25337673 Free PMC article. Review. - Targeting AXL in NSCLC.
Zaman A, Bivona TG. Zaman A, et al. Lung Cancer (Auckl). 2021 Aug 10;12:67-79. doi: 10.2147/LCTT.S305484. eCollection 2021. Lung Cancer (Auckl). 2021. PMID: 34408519 Free PMC article. Review. - Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L. Nabavi N, et al. Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Genes Cancer. 2016. PMID: 28191281 Free PMC article. Review.
References
- Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9 - PubMed
- Clin Cancer Res. 2008 Jan 1;14(1):130-8 - PubMed
- Cancer Res. 2010 Feb 15;70(4):1544-54 - PubMed
- Cell. 2007 Dec 14;131(6):1124-36 - PubMed
- Nat Genet. 2012 Jul 01;44(8):852-60 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous